COMP <GO>
ZTS vs RPRX // 10Y YIELD & FRED MACRO BETA
Zoetis Inc. (NYSE) VS. Royalty Pharma plc (Class A) (NASDAQ) • 15-METRIC TALLY: ZTS 6
— RPRX 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: ZTS
LAST: $79.72 (+1.17%) • MKT CAP: $32.94B
macro-sensitivity
0.99
LAST: $67.18 (+1.90%) • MKT CAP: $38.63B
macro-sensitivity
0.94
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZTS VS. RPRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZTS | RPRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.70% | 7.00% | +18.70 | ZTS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.3x | 27.8x | -17.50 | ZTS | /valuation <GO> |
| Free Cash Flow Yield | 7.01% | 6.29% | +0.72 | ZTS | /fcf-yield <GO> |
| Operating Margin | 34.40% | 65.60% | -31.20 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 28.20% | 32.40% | -4.20 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) | 2.30% | 5.10% | -2.80 | RPRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.53 | 2.90 | +1.63 | ZTS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | RPRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.6 | 72.0 | -12.40 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.99 | 0.94 | +0.05 | ZTS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.3x | 45.8x | -34.50 | ZTS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $32.94B | $38.63B | -$5.69B | RPRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZTS REV | RPRX REV | ZTS GROSS % | RPRX GROSS % | ZTS FCF | RPRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.47B | $2.38B | 71.8% | — | $2.28B | $2.38B |
| FY 2024 | $9.26B | $2.26B | 70.6% | — | $2.30B | $2.67B |
| FY 2023 | $8.54B | $2.35B | — | — | $1.97B | $2.88B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZTS // BETA 0.99
RPRX // BETA 0.94